⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
DYN News
Dyne Therapeutics, Inc. Common Stock
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
globenewswire.com
DYN
IFA 2026 : l'innovation, faiseuse d'avenir
prnewswire.com
SONY
CECO
DYN
JBL
SEG
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
globenewswire.com
DYN
Dyne Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com
DYN
Buckeye Partners Announces Donald R. Sinclair as Chairman
globenewswire.com
WES
DUK
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DYN
Form 8-K
sec.gov
DYN
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
globenewswire.com
DYN
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
globenewswire.com
DYN
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
DYN